Tislelizumab
- Generic Name
- Tislelizumab
- Brand Names
- Tevimbra, Tizveni
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1858168-59-8
- Unique Ingredient Identifier
- 0KVO411B3N
- Background
Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
- Indication
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤（R/R cHL）患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌（NSCLC）患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
- Associated Conditions
- -
- Associated Therapies
- -
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment.
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Xiangdong Cheng
- Target Recruit Count
- 134
- Registration Number
- NCT06374901
- Locations
- 🇨🇳
Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China
PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2024-04-19
- Target Recruit Count
- 60
- Registration Number
- NCT06375109
Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Target Recruit Count
- 85
- Registration Number
- NCT06366945
Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Zhongnan Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06363708
- Locations
- 🇨🇳
The Central Hospital of Wuhan, Wuhan, Hubei, China
🇨🇳Hubei maternal and child health care hospital, Wuhan, Hubei, China
🇨🇳Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 30
- Registration Number
- NCT06357598
- Locations
- 🇨🇳
the Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-04-10
- Target Recruit Count
- 33
- Registration Number
- NCT06356675
TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.
- Conditions
- Interventions
- First Posted Date
- 2024-04-09
- Last Posted Date
- 2024-08-09
- Target Recruit Count
- 30
- Registration Number
- NCT06353360
- Locations
- 🇨🇳
Huashan Hospital affiliated to Fudan University, Shanghai, China
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-04-05
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Sichuan University
- Target Recruit Count
- 9
- Registration Number
- NCT06349837
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT06333769
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 300
- Registration Number
- NCT06333561
- Locations
- 🇨🇳
Chinese PLA General hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.